Mode
Text Size
Log in / Sign up

Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depressionNew ways to define treatment resistant depression are emerging

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that inconsistent TRD definitions and patient non-adherence may lead to the misidentification of pseudo-resistance.

This narrative review explores the complexities of defining treatment-resistant depression (TRD) and identifies critical gaps in current diagnostic frameworks. The authors highlight that existing definitions are hampered by substantial heterogeneity and inconsistent operationalization across research and clinical settings, often relying solely on a specific number of failed antidepressant trials.

The synthesis suggests that several factors may contribute to pseudo-resistance, including variability in clinical assessment, patient comorbidities, treatment non-adherence, and the overall adequacy of therapeutic trials. While evidence regarding genetic, inflammatory, cognitive, and personality correlates of TRD shows promising signals, these areas currently contain persistent gaps.

Clinical practice is impacted by these inconsistencies, as standardized phenotyping is necessary for improved management and precision psychiatry. The authors note that while measurement-based care and algorithm-guided treatment are discussed as potential tools, the review does not provide specific clinical trial data to support these interventions.

How this fits prior evidence

This narrative review addresses a gap in the current understanding of TRD phenotypes. While prior evidence noted no significant association between BDNF genotypes and remission in major depressive disorder, this review highlights that broader biological correlates including genetic and inflammatory factors show promising but incomplete signals for identifying treatment-resistant cases.

Living with depression that does not respond to standard treatments is incredibly hard for patients and doctors alike. Currently, many experts define this condition simply by counting how many medications a person has tried without success. However, this method is often inconsistent and makes it difficult to provide the right care for everyone.

Researchers are looking for better ways to identify these cases. They found that things like poor treatment adherence or other health issues can sometimes look like a drug just isn't working. This is called pseudo-resistance. By looking closer at these factors, doctors may be able to tell the difference between a patient who needs a new approach and one whose current plan just needs better management.

The review also highlights how biology might play a role. While we still have gaps in our knowledge, there are promising signs that genetics, inflammation, and personality traits could help predict which patients will struggle most. Moving toward more specific definitions helps move the field toward precision psychiatry, where treatment is tailored to the individual's unique profile.

What this means for you:
Better ways to define treatment-resistant depression can help doctors provide more precise care for patients.

Common questions

Why is it hard for doctors to treat some types of depression?

Current definitions are often inconsistent because they rely mostly on the number of failed antidepressant trials. This lack of a clear, uniform definition makes it harder for doctors to identify exactly why a patient's treatment isn't working and how to adjust their care plan effectively.

What is pseudo-resistance in depression?

Pseudo-resistance happens when a condition looks like the medication is failing, but it is actually caused by other factors. These can include issues with treatment adherence, other health conditions, or inconsistent clinical assessments during the trial period.

Can biology help predict how someone will respond to treatment?

There are promising signs that genetics, inflammation, and personality traits could help identify patterns in treatment-resistant depression. While there are still gaps in our knowledge, these biological markers offer a path toward more precise medical care.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Treatment-resistant depression (TRD) represents a major clinical and public health challenge contributing disproportionately to disability, healthcare utilisation, and societal costs. Progress in the field may be hindered by substantial heterogeneity in TRD phenotypic definitions and inconsistencies in their operationalisation across research and clinical settings. In this narrative review, we provide an updated overview of TRD research, focusing on limitations of current phenotypic frameworks, key sources of heterogeneity, and emerging biologically informed predictive approaches. We examine how variability in clinical assessment, comorbidities, treatment adherence, and adequacy of therapeutic trials may contribute to pseudo-resistance and consequent phenotypic instability, given that current TRD definitions largely rely on the number of failed antidepressant trials. Evidence on genetic, inflammatory, cognitive, and personality correlates of TRD is also summarised, highlighting both promising signals and persisting gaps. In addition, we discuss the potential role of measurement-based care and algorithm-guided treatment strategies in improving TRD identification and management. Overall, convergence toward more standardised TRD phenotyping—particularly through systematic assessment of adherence and symptom dimensions—appears essential to enhance ecological validity, support precision psychiatry, and advance translational research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.